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Abstract
Background: Authors in previous studies demonstrated that centralising acute stroke care is associated with an
increased chance of timely Intra-Venous Thrombolysis (IVT) and lower costs compared to care at community
hospitals. In this study we estimated the lower bound of the causal impact of centralising IVT on health and cost
outcomes within clinical practice in the Northern Netherlands.
Methods: We used observational data from 267 and 780 patients in a centralised and decentralised system, respectively.
The original dataset was linked to the hospital information systems. Literature on healthcare costs and Quality of Life
(QoL) values up to 3 months post-stroke was searched to complete the input. We used Synthetic Control Methods (SCM)
to counter selection bias. Differences in SCM outcomes included 95% Confidence Intervals (CI). To deal with unobserved
heterogeneity we focused on recently developed methods to obtain the lower bounds of the causal impact.
Results: Using SCM to assess centralising acute stroke 3 months post-stroke revealed healthcare savings of $US 1735 (CI,
505 to 2966) while gaining 0.03 (CI, − 0.01 to 0.73) QoL per patient. The corresponding lower bounds of the causal impact
are $US 1581 and 0.01. The dominant effect remained stable in the deterministic sensitivity analyses with $US 1360 (CI,
476 to 2244) as the most conservative estimate.
Conclusions: In this study we showed that a centralised system for acute stroke care appeared both cost-saving and
yielded better health outcomes. The results are highly relevant for policy makers, as this is the first study to address the
issues of selection and unobserved heterogeneity in the evaluation of centralising acute stroke care, hence presenting
causal estimates for budget decisions.
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Background
The care that patients receive following hospital discharge
largely determined the high costs of stroke [1, 2]. Treat-
ment with Intra-Venous Thrombolysis (IVT) is cost-
effective as the health benefits outweighed the initial costs
[3, 4]. Although IVT treatment rates have risen in the last
decade [5], there is still substantial undertreatment given
the fact that currently between 8 and 10% of patients were
treated [6, 7], whereas treatment rates up to 30% have been
achieved in optimised and dedicated settings [8]. There are
various reasons for the current undertreatment of patients
with IVT. These can largely be grouped in themes such as
patient delay, performance of the stroke pathway and the
organisational system in place for providing acute care [8].
Centralising care in designated stroke centres resulted in
more patients arriving in time for treatment, improved
outcomes and lowered mortality rates compared to care
provided in community hospitals [9–13]. Potential factors
influencing more timely hospital arrival of patients within
centralised settings were a lower threshold for using ambu-
lance services and preferential routing of patients with
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suspected stroke candidate for acute treatment [14]. Also a
greater awareness and readiness for IVT may exist among
healthcare professionals in a centralised organisational sys-
tem [9]. This can be the result of a combination of experi-
ence and exposure to IVT, continued medical training and
new trainees entering the workforce [15, 16]. Improvement
in outcome is based on a larger proportion of patients
arriving on time for treatment at the hospital and a shorter
time to treatment (door-to-needle time) within the hospital
[9, 17]. In the Northern Netherlands a centralised organisa-
tional system for acute stroke care was developed in which
patients with suspected stroke are transported to a single
tertiary university hospital for acute treatment [9]. We have
learned from previous research that a centralised system
can be associated with a 50% increased chance of treatment
compared to a decentralised system in which treatment is
offered in community hospitals.
Using a probabilistic simulation modelling, a recent study
showed that centralising IVT would substantially lower
mean annual costs per patient compared to improving care
at community hospitals separately [17]. However, the causal
impact of centralising acute stroke care within clinical prac-
tice remained unclear. There is previously demonstrated
that centralising stroke care systems was cost-effective,
improved outcomes and reduced mortality and costs
[3, 18, 19]. Yet, these studies did not adequately coun-
ter the endogeneity in the comparison, which limited a
causal interpretation of the delivered estimates. Specifically,
both selection into centralised stroke care systems and the
inference on assessed outcomes are potentially driven by
other factors. Hence, not taking these (un) observables into
account may have yielded biased estimates, possibly result-
ing in suboptimal policy decisions. In this study we specific-
ally link this omitted variable bias to the coefficient stability,
enabling identification of the lower bound of impact on
cost and health outcomes 3 months post-stroke.
Methods
Stroke system characteristics
In the Northern Netherlands, a centralised and decentralised
stroke care system for acute stroke care co-exist [9]. Within
the centralised system acute stroke treatment is performed
in the University Medical Centre Groningen (UMCG), a ter-
tiary university hospital. Within the catchment area of four
hospitals, arrangements were made with hospitals, General
Practitioners (GPs) and Emergency Medical Services (EMS)
to bypass the local three community hospitals, and transfer
potential stroke victims directly to the UMCG for acute
stroke treatment. Approximately 580.000 inhabitants are
served by the centralised system, with a population density of
250 inhabitants per square kilometer. The decentralised sys-
tem consists of nine community hospitals all offering IVT to
patients with suspected acute stroke in their catchment area.
Both stroke care systems conform to the national guidelines.
All hospitals practice identical protocols for identification of
patients with suspected stroke, triage and 911 systems, am-
bulance transport and finally IVT treatment.. For the patients
within the centralised system this meant possibly bypassing a
community hospital and being taken to a comprehensive
stroke center directly. A total of 1.14 million inhabitants are
served by the decentralised system, with an average popula-
tion density of 189 inhabitants per square kilometer. For the
whole of the Northern Netherlands, geography is quite simi-
lar with low levels of traffic congestion, the absence of moun-
tains and a temperate maritime climate.
Data sources
We used patient-level data from 1047 stroke patients who
were part of a large observational study carried out in the
Northern Netherlands in 2010 over the course of 6 months
[9]. Of these patients, 780 patients were admitted to com-
munity hospitals all part of a decentralised stroke care
system, and 267 patients were admitted to a centralised
stroke care system. The descriptive statistics of the patients
are presented in Table 1. Within the centralised system
ischemic stroke patients from all four hospitals were
considered. The original dataset was linked to the hospital
information systems to acquire additional information for
the calculation of hospital costs, such as length of stay. A
description of the number of stroke presentations at each
included hospital is provided in Table 6 in Appendix.
Approach
We used patient-level data from a previously published
study on a central and decentral stroke care system in the
Northern Netherlands [9]. Costs from onset to treatment
had been collected in prior work [17] and extended by link-
ing the original dataset [9] to the hospital information sys-
tem to include intra-hospital costs. The Costs after hospital
discharge up to 3 months were based on the literature [20].
Table 1 Descriptive statistics
Centralised Decentralised
Number of patients 267 780
Age in years (SD) 70 (14) 73 (13)a
Male (%) 149 (56) 383 (49)a
IVT received (%) 61 (23)b 112 (14)
Median sNIHSS on arrival (IQR) 1 (0–3) 1 (0–3)
Median mRS at 3 months (IQR) 1 (0–5) 2 (0–5)a
Referral GP (%) 101 (38) 437 (56)a
First responder EMS (%) 78 (29) 178 (23)
Transported by EMS (%) 204 (76) 456 (58)b
Median distance to hospital (km) 15.6 9.3b
SD indicates standard deviation; IVT Intravenous Thrombolysis, sNIHSS short
National Institutes of Health Stroke Scale, IQR Interquartile Range, mRS
modified Rankin Scale, GP General Practitioner, EMS Emergency Medical
Services, km kilometer. Inference: a/b indicate significant differences at the 5%/
1% level based on the mean differences of the two systems
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Functional disability and independence at 3 months was
assessed with the modified Rankin Scale (mRS). mRS scores
were subsequently mapped into Quality of Life (QoL)
values using a validated algorithm [21, 22].
Health measures
Short National Institutes of Health stroke scale (sNIHSS)
The sNIHSS is a commonly used scale to measure stroke
severity in the pre-hospital phase, but has also been used in
hospital settings [23]. We used the 5-item sNIHSS, covering
gaze, visual fields, motor function in both legs and language.
The sNIHSS scores were recorded in the original dataset and
used as a measure for patients’ health upon hospital arrival.
Quality of life (QoL) values
The mRS score is a commonly used scale to measure disabil-
ity and independence in stroke victims [24]. The scale con-
sists of seven grades, from 0 to 6, with 0 corresponding to no
symptoms, 5 corresponding to severe disability and 6 to indi-
cate mortality. The mRS scores at 3 months were recorded
in the original dataset and mapped into QoL values between
0 and 1 using a validated algorithm [21], implemented with
the corresponding STATA package mrs2eq [22].
The EQ. 5D questionnaire is a standardized instru-
ment developed by the EuroQol Group as a measure of
QoL that can be used in a wide range of health condi-
tions and treatments [25]. The QoL values were used as
a one-time measure for patients’ health at 3 months post
stroke. Pre-stroke QoL values were missing, making the
calculation of Qualtiy-Adjusted Life Years (QALYs) not
straightforward as information on time spent within the
first 3 months is missing.
Cost calculation
The health care use of both systems was ascertained and
valued. Unit costs were obtained from the Dutch Manual
of Costing [26]. The costs associated with healthcare use
are presented in Table 2. The original dataset [9] was
linked to the hospital information systems to collect the
intra-hospital costs. Data linkage with the hospital infor-
mation system, PoliPlus, was requested by the researchers
and performed by hospital’s neurology department. All
patients in the original dataset [9] were linked with the
system. Costs in the post-hospital phase were based on
cost estimates previously published in a Dutch setting [21]
combined with the observed destination and functional in-
dependence at hospital discharge. Costs were determined
from a healthcare provider perspective. Productivity losses
due to functional impairments were not considered, since
the average age of the sample is above retirement age and
relevant measures for the sample below retirement age
were not available in the dataset.
Pre-hospital costs
Pre-hospital costs were based on mode of referral (GP, 911,
self-referral, or intra-hospital), ambulance transportation
and distance covered by EMS [17]. The indicators were
multiplied with the unit prices as presented in Table 2.
Intra-hospital costs
Intra-hospital costs were based on whether the patient
was treated with IVT, length-of-stay in the acute stroke
unit and length-of-stay in the neurology ward. For this,
the original dataset was linked to the hospital information
system which contains detailed medical information on
length of stay at the neurology department. Differences in
staffing costs between university medical centres and
community hospitals were taken into account [26].
Costs after hospital discharge
Costs after hospital discharge up to 3 months were not
directly observed. We adopted the strategy of Dirks et al.
[20] and related mRS scores at 3 months to average health-
care use after discharge. Patients in the mRS 0–1 category
were presumed to be discharged home with no extra costs.
Patients in the mRS 2–3 category were presumed to be
discharged home with additional home care (1 h/day) and
Table 2 Unit costs associated with healthcare use




Visit by general practitioner $56.00
Emergency medical services transport (2)
Emergency transport $882.00
Dispatch $71.00
Per driven kilometer $5.00
Medical personnel ER visit (1)
Medical specialist (15 min) $44.38
Resident (1 h) $36.48
Nurse (1 h) $35.04
Outpatient clinic visit $89.60 (1)
Computed tomography scan $144.48 (3)
Central laboratory (per test) $27.10 (4)
Alteplase $532.46 (5)
Neurology ward (1 day) $466.10 (1)
Stroke unit (1 day) $626.68 (3)
Care after discharge (1)
Home care (1 day) $59.00
Remedial therapy (1 session) $38.94
Rehabilitation centre (1 day) $542.80
Nursing home (1 day) $198.24
$US indicates United States dollar; ER, emergency room. (1) Dutch manual of
costing [26]; (2) Data from regional ambulance services Groningen; (3) Dirks et al.,
2012 [20]; (4) Claes et al., 2006 [27]; (5) www.medicijnkosten.nl [28]
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remedial therapy costs (3 sessions/week). Patients in the
mRS 4 category were discharged (depending on age) to a
rehabilitation centre (if younger than 65 years) or a nursing
home (if aged 65 years or older). Patients in the mRS 5 cat-
egory were discharged to a nursing home. mRS 6 category
means deceased with no extra costs.
Adjustment for timing and currency
The index year is 2019. Therefore, costs are corrected with
an average annual inflation rate of 1.015% [29]. Furthermore,
since costs were collected from a healthcare provider
perspective, cost prices are converted using the current Pur-
chasing Power Parity (PPP) of 1.2642$US per 1 Euro [30].
Statistical analysis
Mean differences in the patients’ characteristics, costs
and health outcomes were determined with independent
samples t-tests (normal distribution) or Mann-Whitney
U tests (skewed distribution). Mean differences tests on
the cost and health outcomes indicated that mean re-
gressions could be used for the estimation.
The regression formulation of the evaluation in this
study is given by
Y i ¼ c0 þ β CSi þ γ  X i þ ei; ð1Þ
where Yi is the outcome of interest (cost, health) for indi-
vidual i, c0 the intercept, CSi is a binary variable for the
stroke care system with the centralised stroke system as ref-
erence category with β as the corresponding coefficient, Xi
are the control variables gender, age, IVT received, mode of
referral, stroke severity on arrival, and transported by EMS
with γ as the vector of corresponding coefficients and ei
denotes the error term. Distance to hospital was excluded
as control variable due to collinearity with the system indi-
cator variable CSi. As mentioned above, Ordinary Least
Squares (OLS) regression of eq. (1) yields a biased estimate
of β, as both selection into centralised stroke care systems
and the inference on assessed outcomes are potentially
driven by other factors, i.e. E[Yi| ei] ≠ 0.
To counter selection bias we use Synthetic Control
Methods (SCM) and estimate eq. (1) in two stages. In the
first stage we estimate the individual propensity scores of
selection in a centralised stroke care system conditional
on the control variables Xi with a logit model denoted by
pi ¼ Pr CSi ¼ 1½ jX i ð2Þ
where we followed Rosenbaum and Rubin (1985) and used a
preset caliper size of a quarter of a standard deviation of the
logit of the propensity score [31, 32]. Mean differences of the
raw and matched data and balance plots were used to assess
the balancing assumption in the first stage. Subsequently, in
the second stage we use the predicted values pi of eq. (2) to
obtain the Average Treatment Effect (ATE),
E Y ið jCSi ¼ 1;X iÞ−E Y ið jCSi ¼ 0;X iÞ ð3Þ
The SCM does not control for unobserved heterogeneity,
i.e. factors related to the inference on β that were not ob-
served in the dataset (e.g., socioeconomic status). Therefore,
to assess to what extent the inference on coefficient β in eq.
(1) is affected by (un) observables we link the omitted vari-
able bias to the coefficient stability using the Altonji ratio
[33, 34]. Subsequently, we implement a recently published
estimator [35] to obtain the lower bound of the causal ef-
fect of centralising acute stroke care denoted by





where RF (RR) and β̂F (β̂R) are the R-squared and obtained
estimate of OLS regression on the full (restricted) model
of equation (1), respectively, and RMAX is the maximum
R-squared. The calculation of RMAX is pre-determined.
For example, Bellows & Miquel (2009) suggest RMAX
equals RF + (RF − RR) [36]. For that case, Angelini &
Mierau (2018) show that β̂ then reduces to 2β̂F−β̂R ,
which is a straightforward way to assess β̂ without further
knowledge of the underlying R-squared [37]. Alternatively,
Oster (2017) suggest RMAX equals 1.3 × RF [35], deter-
mined from published randomized controlled trials in
leading economic journals between 2008 and 2013. We
adopted the latter option, as it incorporates both the coef-
ficient movement and the model’s fit.
Deterministic sensitivity analyses were undertaken to test
the stability of the observed estimates. First, we focused on
the mapping method of the QoL values. In the sensitivity
analysis we used the second validated algorithm of Rivero-
Arias et al. (2010) [21] and replicated the OLS regression
option using Monte Carlo simulation with 10,000 itera-
tions, again implemented with the STATA package mrs2eq
[22]. Second, we focused on the uncertainty underlying the
cost derivation of costs after hospital discharge, as this part
is largely determined from previously published cost esti-
mates for the Dutch setting [20]. Specifically, we modified
the assumptions in the main analysis and presumed that
patients in the mRS 4 category either go home during the
weekends or receive informal care half a week.
Differences in outcomes include 95% Confidence Inter-
vals (CI). All of above statistical analyses were performed
with STATA/SE 15.0 (STATA; https://www.stata.com/).
Results
Comparing stroke care systems
A summary on patient recruitment, baseline patient
characteristics, access to healthcare services and health
outcomes of both stroke care systems is provided in Table
1. Mean differences were determined with independent
samples t-tests (normal distribution) or Mann-Whitney U
tests (skewed distribution). We observed that while stroke
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severity on arrival does not differ between the two systems
(P = 0.132), at 3 months after hospital discharge the level
of disability and dependence is greater in the decentralised
system than in the centralised system (P = 0.012).
In Table 3 the cost composition of both systems is
provided. We observed that while the mean pre-hospital
costs were greater for the centralised system (P = 0.000),
the total costs up to 3 months were less than for the
decentralised system (P = 0.009).
Estimation results
Synthetic control methods
As mentioned above, we followed Rosenbaum and Rubin
(1985) and used a preset caliper size of a quarter of a
standard deviation of the logit of the propensity score [31,
32]. No observations were excluded. The systems were
balanced in the first stage on the included covariates, as
demonstrated with mean differences of the raw and
matched data in Table 7 in Appendix and illustrated in
the balance plot in Figure 1 in Appendix. The balancing
assumption enables to estimate the ATE in the second
stage. Using SCM we obtain a β̂ for healthcare savings and
QoL gain of $US 1735 (CI, 505 to 2966) (P = 0.006) and
0.03 (CI, − 0.01 to 0.73) (P = 0.093), respectively.
Causal approach
In Tables 4 and 5 we present the restricted and full coeffi-
cients for β in equation (1) for incremental healthcare
costs and QoL values, respectively. Using β̂R and β̂F in the
first row in combination with RR and RF in the last row
enables to determine the lower bounds of the causal effect
according to equation (4) [35]. Hence, centralising acute
stroke leads to a lower bound causal effect on healthcare
savings and QoL gain of $US 1581 and 0.01 respectively.
Sensitivity analyses
Deterministic sensitivity analyses were undertaken to test the
stability of the observed dominant causal effect of centralising
acute stroke care. First, implementing the second validated
algorithm to mapp QoL values from the observed mRS
scores revealed no change in results (P= 0.124). Second,
adopting the alternative assumptions underlying the deriv-
ation of cost after hospital discharge in the SCM yields
healthcare savings of $US 1561 (CI, 524 to 2597) (P= 0.003)
and $US 1360 (CI, 476 to 2244) (P= 0.003), respectively.
Discussion
In this study we evaluated the causal impact of a centralised
stroke care system on healthcare costs and QoL values up to
3 months after hospital discharge, compared to a decentra-
lised stroke care system. To this end we linked the original
dataset [9] to the hospital information system comprising
patient-level data and used previously published cost
estimates [20] and algorithms [21, 22]. We show that centra-
lising IVT lowers costs and increases patients’ health –
Table 3 Cost composition ($US)
Centralised Decentralised
Mean pre-hospital costs (CI) 1023** (954–1092) 760 (715–805)
Mean intra-hospital costs (CI) 3722** (3611 – 3832) 3920 (3854 – 3986)
Mean costs after
hospital discharge (CI)
3605** (2630 – 4580) 5232 (4669 – 5795)
Mean total costs (CI) 8332** (7271 – 9394) 9944 (9317 – 10,571)
Inference: ** indicate significant differences at the 1% level based on the
mean differences of the two systems
Table 4 OLS regression results: healthcare costs (N = 1047)
Total costs at 3 months ($US) Restricted Full
Centralised − 1704a (626) − 1611b (626)
Gender 1255a (522)
Age 25–45 (baseline)
Age 46–65 2150a (931)
Age 65–96 2317b (661)





SNIHSS on arrival 762b (139)
Transported by EMS 2847b (661)
Constant 9944b (319) 3838b (808)
R-squared 0.0063 0.1020
GP General Practitioner, sNIHSS short National Institutes of Health Stroke Scale,
EMS Emergency Medical Services. Robust standard errors are presented in the
parentheses. Inference: a/b indicate significant differences at the 5%/1% level
Table 5 OLS regression results: QoL utility values (N = 1047)
EQ 5D at 3 months Restricted Full
Centralised 0.039 (0.022) 0.018 (0.019)
Gender −0.029a (0.016)
Age 25–45 (baseline)
Age 46–65 − 0.027 (0.021)
Age 65–96 −0.126b (0.020)





SNIHSS on arrival −0.055b (0.003)
Transported by EMS −0.053a (0.021)
Constant 0.651b (0.011) 0.906b (0.023)
R-squared 0.0033 0.3017
QoL Quality of Life, GP General Practitioner, sNIHSS short National Institutes of
Health Stroke Scale, EMS Emergency Medical Services. Robust standard errors
are presented in the parentheses. Inference: a/b indicate significant differences
at the 5%/1% level
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proving dominance over the decentralised system. On aver-
age, the lower bound of the causal impact on healthcare sav-
ings was $US 1581, while similarly health outcomes in terms
of QoL gain were 0.014 higher. Indeed, studies that did not
adequately account for omitted variables bias may have over-
estimated the effects of centralising IVT, potentially leading
to suboptimal budget allocation if adopted by policy makers.
The results are mainly determined by the differences in pa-
tient health, as measured with mRS scores, in both stroke
care systems. This corroborates our expectation that
patients’ health is influenced by the organisation of the
healthcare system. Although pre-hospital costs were greater
in a centralised system, on average a larger portion of
patients in the centralised system become functionally inde-
pendent again at 3 months (mRS scores 0–1), thereby saving
significant healthcare costs by avoiding care in either a nurs-
ing home or rehabilitation centre. This is could suggest that
higher pre-hospital costs for the centralised system are offset
by a decreased length-of-stay in the hospital and avoiding
institutional care after hospital discharge due to improved
patients’ health. These results suggest that centralising
services could contribute to further improving healthcare, as
short-term stroke severity is an important predictor of QoL
years after the stroke [38]. From a societal perspective it
would be interesting to see whether centralisation of acute
stroke care would lead to a shift in costs associated with
productivity, informal care and additional transport for care-
givers. Better outcomes as obtained in the centralised system
would have led to higher productivity, and thus added to a
more favourable cost difference. Indeed, dominance would
have only increased. Furthermore, also the long-term costs
incurred for informal care would have been lower in the cen-
tralised system, simply as fewer stroke victims would need
less of it. Further research is needed to prove these argu-
ments, as data on productivity, informal care and additional
transport costs for caregivers are missing in this study.
It is increasingly recognized that stroke care systems centra-
lised at highly specialised tertiary hospital may generate better
patient outcomes at lower costs, compared to care offered at
community hospitals [12, 39]. Nationally acute stroke care
treatment consists of admission to a stroke unit and treat-
ment with IVT, which is currently administered to approxi-
mately 15% of the Dutch incident stroke population [9]. Due
to an ageing population the number of patients receiving
acute treatment is expected to increase substantially in the
near future. Expanding services to other hospitals and regions
therefore appears to provide great potential for economic as
well as patient value. Importantly, costs per patient will likely
decrease with large patient volumes due to economies of scale
associated with lower training costs of medical specialists and
overhead costs for materials and equipment. Additionally,
more costly because of economies of scale certainly will apply
also in the Netherlands, yet rurality of the Netherlands may
be a relative issue. The nearest comprehensive stroke center
will hardly ever be further out than say 50 kms. Indeed in a
Scandinavian, US or Canadian settings this may be a different
issue. In such settings travel time will become a real issue up
to a point where certain services simply may no longer be ac-
cessible. In acute stroke telemedicine, not taken into account
in this study, may become a viable option.
We acknowledge that our study design has some limita-
tions. For example, patient-level data could not be retrieved
for actual costs made by patients after hospital discharge.
Therefore, we relied on previously published cost estimates
in a Dutch setting [20]. We acknowledge this affects the
size of the estimate for incremental healthcare costs, but we
argue it would not have altered out conclusions, as it has
been shown in the literature that healthcare costs increase
with functional disability and dependence [3–5, 16–20].
Furthermore, after manipulating the assumptions under-
lying healthcare use in the deterministic sensitivity analyses,
we found that the coefficient only changed moderately.
Hence, the dominant effect remained stable. To further
understand the effect of centralised stroke care systems on
societal costs within clinical practice, future studies may
consider following cohorts prospectively from onset to 3
months post-stroke. Furthermore, stroke severity may have
been slightly underestimated by using the 5-item short ver-
sion of the NIHSS. The sNIHSS has been validated for the
pre-hospital setting, however the subset of impairments
scored is still lower compared to the full version of the
NIHSS potentially leading to loss of information on stroke
severity. However, this will marginally affect our results, as
the sNIHSS is only included as control variable.
Since the results suggest centralising IVT is both cost sav-
ing and yields better health outcomes, we dare conclude
dominance in terms of cost-effectiveness. We acknowledge
that a full cost-utility analysis requires to adopt the Consoli-
dated Health Economic Evaluation Reporting Standards
(CHEERS) [40]. This is not feasible as important compo-
nents are missing in the dataset. For example, extrapolating
the results over patients’ lifetime would introduce too much
uncertainty, as we would have to rely on transition rates
from the literature since follow-up data within applicable
cycle-lengths is missing. The latter, however, would not
alter the outcome of dominance as after initial treatment
failure or success the long-term prognosis is more or less
determined, i.e., a higher initial success rate implies both
lower long-term costs as well as health benefits [38].
Conclusions
From this study we conclude that a centralised system for
acute stroke care lowers healthcare costs and improves
health outcomes within clinical practice. The results are
highly relevant for policy makers, as this is the first study to
address the issues of selection and unobserved heterogeneity
in the evaluation of centralising acute stroke care, hence pre-
senting causal estimates for budget decisions.
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Appendix












Refaja hospital, Stadskanaal 123 112
Decentralized system
Martini hospital, Groningen 380 332




Hospital Nij Smellinghe, Drachten 265 223
Antonius hospital, Sneek 230 203
Treant care group, location
Scheper, Emmenc
319 273
Wilhelmina hospital, Assen 266 216
Diaconessenhuis hospital, Meppel 224 202
Hospital Bethesda, Hoogeveen 83 70
aNumber were taken from an online data repository of the National Health
Care Institute (https://www.zorginstituutnederland.nl/) containing data from
October 2014 till September 2015
bThe Ommelander care group, Groningen consists of two community hospital
both part of the central system
cTreant care group, location Scheper, Emmen did not participate in the
observational study performed in 2010 (9)
Table 7 Comparison of mean differences in raw and matched
data
Raw Matched
Age in years -0.1978049a -0.0796457
Male 0.1285413a 0.0057671
IVT received -0.2216757b -0.058478
sNIHSS on arrival 0.1092078 0.0387365
Mode of referral 0.2681143a 0.0242103
Transported by EMS (%) 0.3942428b 0.025803
IVT Intravenous Thrombolysis, sNIHSS short National Institutes of Health Stroke
Scale, EMS Emergency Medical Services, km kilometer. Inference: a/b indicate
significant differences at the 5%/1% level based on the mean differences of
the two systems
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Years; QoL: Quality of Life; SCM: Synthetic Control Methods; sNIHSS: short





RDF – Reports no disclosures
JOM – Reports no disclosures
EB – Reports no disclosures
EP – was supported by the National Institute for Health Research (NIHR)
Collaboration for Leadership in Applied Health Research and Care North
Thames at Barts Health NHS Trust. The views expressed are those of the
authors and not necessarily those of the NHS, the NIHR or the Department
of Health
GJL – Reports no disclosures
DJZ – Reports no disclosures
MMHL – Reports no disclosures
Authors’ contributions
RDF – study concept and design, statistical analyses, drafting the manuscript.
JOM – study concept and design, statistical analyses, critical revision of the
manuscript for intellectual content. EB – critical revision of the manuscript
for intellectual content. EP – critical revision of the manuscript for intellectual
content. GJL – critical revision of the manuscript for intellectual content. DJZ
– critical revision of the manuscript for intellectual content. MMHL – study
concept and design, study supervision, drafting the manuscript, critical
revision of the manuscript for intellectual content. All authors read and
approved the final manuscript.
Funding
N/A
Availability of data and materials
The data that support the findings of this study are available from the UMCG
but restrictions apply to the availability of these data, which were used
under license for the current study, and so are not publicly available. Data
are however available from the authors upon reasonable request and with
permission of UMCG.
Ethics approval and consent to participate
We have permission from the Medical Ethics Committee of the University of
Groningen to conduct this research (contact: + 31 (0)50 361 4204). This study
is related to the original IMPACT study. Individuals in the dataset are aware
of the use of hospital information as input for the analysis.
Consent for publication
We have permission on behalf of the individuals (or relatives) from which
individual patient data is used to publish the conducted results.
Competing interests
The authors declare that they have no competing interests.
Author details
1Department of Economics, Econometrics & Finance, Faculty of Economics &
Business, University of Groningen, Groningen, The Netherlands. 2Unit Patient
Centred Health Technology Assessment, Department of Epidemiology,
University of Groningen, University Medical Centre Groningen, Groningen,
The Netherlands. 3Aletta Jacobs School of Public Health, Groningen, The
Netherlands. 4Department of Operations, Faculty of Economics & Business,
University of Groningen, Groningen, The Netherlands. 5Department of
Applied Health Research, Faculty of Population Health Sciences, University
College London, London, England. 6Department of Neurology, University of
Groningen, University Medical Centre Groningen, Groningen, The
Netherlands.
Received: 30 January 2020 Accepted: 5 February 2020
References
1. Demaerschalk BM, Hwang HM, Leung G. US cost burden of ischemic stroke:
a systematic literature review. Am J Manag Care. 2010;16:525–33.
2. Dewey HM, Thrift AG, Mihalopoulos C, et al. Cost of stroke in Australia from
a societal perspective: results from the north East Melbourne stroke
incidence study (NEMESIS). Stroke. 2001;32:2409–16.
3. Guzauskas GF, Boudreau DM, Villa KF, et al. The cost-effectiveness of primary
stroke centers for acute stroke care. Stroke. 2012;43:1617–23.
4. Tan Tanny SP, Busija L, Liew D, et al. Cost-effectiveness of thrombolysis
within 4.5 hours of acute ischemic stroke: experience from Australian stroke
center. Stroke. 2013;44:2269–74.
5. Fang MC, Cutler DM, Rosen AB. Trends in thrombolytic use for ischemic
stroke in the United States. J Hosp Med. 2010;5:406–9.
6. Bauer A, Limburg M, Visser MC. Variation in clinical practice of intravenous
thrombolysis in stroke in the Netherlands. Cerebrovasc Dis Extra. 2013;3:74–7.
Fig. 1 Balance plot of raw and matched data
Freriks et al. BMC Health Services Research          (2020) 20:103 Page 8 of 9
7. Adeoye O, Hornung R, Khatri P, et al. Recombinant tissue-type plasminogen
activator use for ischemic stroke in the United States: a doubling of
treatment rates over the course of 5 years. Stroke. 2011;42:1952–5.
8. Boode B, Welzen V, Franke C, et al. Estimating the number of stroke patients
eligible for thrombolytic treatment if delay could be avoided. Cerebrovasc
Dis. 2007;23:294–8.
9. Lahr MM, Luijckx GJ, Vroomen PC, et al. Proportion of patients treated with
thrombolysis in a centralised versus a decentralised acute stroke care
setting. Stroke. 2012;43:1336–40.
10. Bekelis K, Marth NJ, Wong K, et al. Primary stroke center hospitalization for
elderly patients with stroke: implications for case fatality and travel times.
JAMA Intern Med. 2016;176:1361–8.
11. Morris S, Hunter RM, Ramsay AI, et al. Impact of centralising acute stroke
services in English metropolitan areas on mortality and length of hospital
stay: difference-in-differences analysis. BMJ. 2014;349:g4757.
12. Rinaldo L, Brinjikji W, Rabinstein AA. Transfer to high-volume centers
associated with reduced mortality after endovascular treatment of acute
stroke. Stroke. 2017;48:1316–21.
13. Ramsay AI, Morris S, Hoffman A, et al. Effects of Centralising acute stroke
services on stroke care provision in two large metropolitan areas in
England. Stroke. 2015;46:2244–51.
14. Lahr MM, Vroomen PC, Luijckx GJ, et al. Prehospital factors determining
regional variation in thrombolytic therapy in acute ischemic stroke. Int J
Stroke. 2014;9(Suppl A100):31–5.
15. Leira EC, Pary JK, Davis PH, et al. Slow progressive acceptance of
intravenous thrombolysis for patients with stroke by rural primary care
physicians. Arch Neurol. 2007;64:518–21.
16. Grotta JC, Burgin WS, El-Mitwalli A, et al. Intravenous tissue-type
plasminogen activator therapy for ischemic stroke: Houston experience
1996 to 2000. Arch Neurol. 2001;58:2009–13.
17. Lahr MM, van der Zee DJ, Luijckx GJ, et al. Centralising and optimising
decentralised stroke care systems: a simulation study on short-term costs
and effects. BMC Med Res Methodol. 2017;17:5.
18. Hunter RM, Davie C, Rudd A, et al. Impact on clinical and cost outcomes of
a centralised approach to acute stroke care in London: a comparative
effectiveness before and after model. PLoS One. 2013;8:e70420.
19. Ganesalingam J, Pizzo E, Morris S, et al. Cost-utility analysis of mechanical
Thrombectomy using stent retrievers in acute ischemic stroke. Stroke. 2015;
46:2591–8.
20. Dirks M, Baeten SA, Dippel DW, et al. Real-life costs and effects of an
implementation program to increase thrombolysis in stroke. Neurology.
2012;79:508–14.
21. Rivero-Arias O, Ouellet M, Gray A, et al. Mapping the modified Rankin scale
(mRS) measurement into the generic EuroQol (EQ-5D) health outcome. Med
Decis Mak. 2010;30:341–54.
22. Ramos-Gonñi JM, Rivero-Arias O, Dakin H. Response mapping to
translate health outcomes into the generic health-related quality-of-life
instrument EQ-5D: introducing the mrs2eq and oks2eq commands.
Stata J. 2013;13:474–91.
23. Tirschwell DL, Longstreth WT Jr, Becker KJ, et al. Shortening the NIH stroke
scale for use in the prehospital setting. Stroke. 2002;33:2801–6.
24. Rankin J. Cerebral vascular accidents in patients over the age of 60. II.
Prognosis. Scott Med J. 1957;2:200–15.
25. EuroQol Group. EuroQol--a new facility for the measurement of health-
related quality of life. Health Policy. 1990;16:199–208.
26. Hakkaart-van Roijen L, van der Linden N, Bouwmans C, et al. Kostenhandleiding:
Methodologie van kostenonderzoek en referentieprijzen voor economische




gezondheidszorg+(verdiepingsmodules).pdf. Accessed 5 Oct 2017.
27. Claes N, Moeremans K, Frank B, et al. Estimating the cost-effectiveness of
quality-improving interventions in oral anticoagulation management within
general practice. Value Health. 2006;9:369–76.
28. Zorginstituut Nederland (2019). Medicijnkosten.nl. https://www.
medicijnkosten.nl/ Accessed 12 Feb 2019.
29. OECD. Stat (2019). Consumer price indices (CPIs): annual inflation. https://
statsoecdorg/indexaspx?queryid=82174 Accessed 12 Feb 2019.
30. OECD. Stat (2019). Purchasing Power Parities for GDP and related indicators.
https://stats.oecd.org/Index.aspx? DataSetCode=PPPGDP Accessed 12 2019.
31. Imbens GW, Rubin DB. Causal Inference for Statistics, Social, and Biomedical
Sciences: An Introduction. London: Cambridge University Press; 1900. p. 2015.
32. Drummond MF, Sculpher MJ, Claxton K, et al. Methods for the economic
evaluation of health care programs. Oxford: Oxford University Press; 2015.
33. Rosenbaum PR, Rubin DB. Constructing a control group using multivariate
matched sampling methods that incorporate the propensity score. Am Stat.
1985;39:33–8.
34. Altonji JG, Elder TE, Taber CR. Selection on observed and unobserved
variables: assessing the effectiveness of Catholic schools. J Polit Econ. 2005;
113:151–84.
35. Altonji JG, Elder TE, Taber CR. Using selection on observed variables to
assess bias from unobservables when evaluating swan-ganz catheterization.
Am Econ Rev. 2008;98:345–50.
36. Oster E. Unobservable selection and coefficient stability: theory and
evidence. J Bus Econ Stat. 2018;37:1–18.
37. Bellows J, Miguel E. War and local collective action in Sierra Leone. J Public
Econ. 2009;93:1144–57.
38. Angelini V, Mierau J. Late-life health effects of teenage motherhood.
Demogr Res. 2018;39:1081–104.
39. Berkhemer OA, Fransen PS, Beumer D, et al. A randomized trial of intraarterial
treatment for acute ischemic stroke. N Engl J Med. 2015;372:11–20.
40. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D,
et al. Consolidated health economic evaluation reporting standards
(CHEERS) statement. Cost Effect Res Alloc. 2013;11:6.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Freriks et al. BMC Health Services Research          (2020) 20:103 Page 9 of 9
